Previous 10 | Next 10 |
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q4 2020 Earnings Call Feb 23, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q4 2020 Earnings Call Transcript
AtriCure, Inc. (ATRC) Q4 2020 Earnings Conference Call February 23, 2021 16:30 ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President & Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Mike Matson - Needham & Company Mat...
AtriCure (ATRC): Q4 Non-GAAP EPS of -$0.18 beats by $0.07; GAAP EPS of -$0.42 misses by $0.13.Revenue of $57.73M (-5.9% Y/Y) misses by $0.23M.Shares -5.03%.Press Release For further details see: AtriCure EPS beats by $0.07, misses on revenue
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results. “Despite challenges posed in 2020 as a result of the...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual Global Healthcare Conference...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021. AtriCure ...
AtriCure ([[ATRC]] +0.8%) expects Q4 revenue to decline ~6% Y/Y and ~+5% M/M to ~$57.7M vs. consensus of $58.11M. FY2020 to drop ~11% Y/Y to $206.5M vs. consensus of $206.97M, impacted by the global decline in surgical procedures as a result of the COVID-19 pandemic. “We are pleased wi...
Fourth quarter 2020 worldwide revenue of $57.7 million (U.S. $47.4 million, International $10.3 million) AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall. AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left at...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...